论文部分内容阅读
目的:评价四联疗法与三联疗法治疗小儿幽门螺杆菌(HP)感染消化性溃疡患者的临床疗效差异及安全性。方法:选取2014年1月—2015年6月间收治的小儿HP感染消化性溃疡患者96例作为研究对象;按照随机分组方法将其分成观察组患者和对照组,各48例;对照组患儿均给予常规三联疗法治疗,观察组患儿均给予四联疗法治疗,比较与评价两组患儿治疗后临床疗效及HP转阴率及不良反应发生率的发生率。结果:观察组患者治疗后HP转阴率(总有效率)为95.83%显著高于对照组为79.17%(P<0.05);观察组患儿不良反应的发生率为6.25%显著低于对照组为25.00%(P<0.05)。结论:四联疗法治疗HP感染消化性溃疡患儿临床疗效优于三联疗法,可提高HP转阴率和有效根除幽门螺杆菌,安全性较高。
Objective: To evaluate the clinical efficacy and safety of quadruple therapy and triple therapy in the treatment of children with peptic ulcer infection of Helicobacter pylori (HP). Methods: A total of 96 patients with peptic ulcer in children with HP infection admitted to our hospital from January 2014 to June 2015 were enrolled in this study. They were divided into observation group and control group according to randomization method, 48 cases in each group. Children in control group Were given conventional triple therapy, the observation group were given quadruple therapy, compare and evaluate the clinical efficacy of two groups of children after treatment and HP negative conversion rate and the incidence of adverse reactions. Results: After treatment, the negative conversion rate (total effective rate) of HP in the observation group was 95.83%, which was significantly higher than that in the control group (79.17%, P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that of the control group Was 25.00% (P <0.05). Conclusion: The quadruple therapy is superior to triple therapy in the treatment of peptic ulcer in children with HP infection, which can improve the conversion rate of HP and effectively eradicate Helicobacter pylori, which is safe.